Drug Trial Radar · NCT02548351
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment
Last checked: Nov 20, 2026Latest source record: Oct 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2,477
Actual
Start
Sep 22, 2015
Primary completion
Sep 15, 2023
Study completion Sep 15, 2023
Sponsor
- Lead sponsor
- Intercept PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Sep 14, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study are to evaluate the effect of Obeticholic Acid treatment compared to placebo on 1) histological improvement and 2) liver-related clinical outcomes in patients with non-cirrhotic nonalcoholic steatohepatitis (NASH) with liver fibrosis.
Conditions
- Non Alcoholic Steatohepatitis (NASH)
Interventions
Obeticholic AcidDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to the First Adjudicated Event for Clinical Outcome Composite Endpoint: Percentage of Participants With an EventTime frame: Up to 7 years
Locations
346 sites in 21 countries. Site status is shown where the registry gives one.
The University of Alabama at Birmingham
Birmingham, Alabama
Digestive Health Specialists of the Southeast
Dothan, Alabama
Institute for Liver Health DBA Arizona Liver Health
Chandler, Arizona
Arizona Liver Health - Glendale
Glendale, Arizona
St. Joseph's Hospital and Medical Center
Phoenix, Arizona
Mayo Clinic Arizona
Phoenix, Arizona
Arizona Liver Clinic - Tucson
Tucson, Arizona
Liver Wellness Center
Little Rock, Arkansas
Arkansas Gastroenterology
North Little Rock, Arkansas
GW Research Inc.
Chula Vista, California
Precision Research Institute
Chula Vista, California
Southern California Research Center
Coronado, California
Citrus Valley Gastroenterology
Covina, California
TriWest Research Associates, LLC
El Cajon, California
UCSF Fresno, Clinical Research Center
Fresno, California
Fresno Clinical Research Center
Fresno, California
Scripps Clinic
La Jolla, California
University of California, San Diego
La Jolla, California
Keck Medical Center of USC
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
National Research Institute, Wilshire
Los Angeles, California
Gastrointestinal Biosciences
Los Angeles, California
Veteran Affairs Great Los Angeles Healthcare System
Los Angeles, California
Stanford University
Palo Alto, California
Inland Empire Liver Foundation
Rialto, California
University of California Davis Medical Center
Sacramento, California
eStudy Site
San Diego, California
Medical Associates Research Group
San Diego, California
Kaiser Permanente
San Diego, California
California Pacific Medical Center (CPMC)
San Francisco, California
UCSF/ San Francisco General Hospital
San Francisco, California
Quest Clinical Research
San Francisco, California
University of California, San Francisco
San Francisco, California
Silicon Valley Research Institute
San Jose, California
University of Colorado Denver and Hospital
Aurora, Colorado
South Denver Gastroenterology, PC
Englewood, Colorado
Western States Clinical Research, Inc.
Wheat Ridge, Colorado
Yale University School of Medicine
New Haven, Connecticut
Integrity Clinical Research, LLC
Doral, Florida
UF Hepatology Research at CTRB
Gainesville, Florida
Showing 40 of 346 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.